Author name: admin

Uncategorized

New Releases from NCBI BookshelfNivolumab Plus Ipilimumab (Opdivo Plus Yervoy): Indication: Opdivo (nivolumab), in combination with ipilimumab, for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma: Reimbursement Recommendation [Internet].​Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy): Indication: Opdivo (nivolumab), in combination with ipilimumab, for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

What Is the Reimbursement Recommendation for Opdivo Plus Yervoy? ​ 

Uncategorized

New Releases from NCBI BookshelfDelgocitinib (Anzupgo): Indication: For the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or are not advisable: Reimbursement Recommendation [Internet].​Delgocitinib (Anzupgo): Indication: For the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or are not advisable: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Anzupgo be reimbursed by public drug plans for the treatment of moderate to severe

Uncategorized

New Releases from NCBI BookshelfVanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek): Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene: Reimbursement Recommendation [Internet].​Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek): Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Alyftrek be reimbursed by public drug plans for the treatment of cystic fibrosis (CF)

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top